Form 4: Pulse Biosciences Director Mahkam Zanganeh Reports Stock and Warrant Transactions

Director Mahkam Zanganeh reports acquisition and disposal of Pulse Biosciences stock and warrants.

Summary

• On January 24, 2025, Director Mahkam Zanganeh acquired 30,121 shares of Pulse Biosciences common stock at $11 per share and disposed of 695,274 shares.
• On February 3, 2025, Zanganeh acquired another 30,121 shares at $11 per share and disposed of 725,395 shares.
• Zanganeh also acquired warrants to purchase 30,121 shares of common stock on both January 24, 2025, and February 3, 2025, with an exercise price of $11.
• The warrants expire on July 3, 2029.
• Zanganeh also has indirect ownership of Pulse Biosciences common stock through immediate family members: 27,000 shares through Immediate Family Member 1, 14,000 shares through Immediate Family Member 2, and 107,074 shares through Immediate Family Member 3.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard regulatory filing detailing stock transactions. There's no inherent positive or negative implication.

Industry Context

This filing is a routine disclosure of insider transactions and doesn't necessarily indicate a broader trend in the medical device industry.

Stakeholder Impact

• The transactions could have a minor impact on shareholder sentiment, depending on how the market interprets the insider's actions.

Key Dates

Keywords

Pulse Biosciences, PLSE, insider trading, Form 4, stock, warrants, director, Zanganeh, acquisition, disposal